Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...
Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...
Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...
One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...
Keytruda’s first-line boost could come soon. Data from Keytruda’s first-line lung cancer study will be presented at the European Society of Medical Oncology meeting in October--the lung cancer study ...
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...
The verdict is the latest twist in patent litigation between MSD and Halozyme, in which the latter is claiming that Keytruda ...
The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to ...
In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...
For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds
For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds A large clinical trial shows that for many patients with the most common type of lung cancer, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback